Simbarashe Chinyowa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Simbarashe Chinyowa has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Godfrey Muguti
Faculty of Medicine and Health Sciences, Department of Surgical Sciences, University of Zimbabwe, Harare, Zimbabwe
2 shared publicationsJennifer Moodley
Faculty of Health Sciences, School of Public Health, University of Cape Town, Cape Town, South Africa
2 shared publications- Godfrey I. Muguti
Department of Surgery, College of Health Sciences, University of Zimbabwe, Zimbabwe, Africa
1 shared publication Grant Murewanhema
University of Zimbabwe Faculty of Medicine and Health Sciences, Harare, Harare Province, Zimbabwe
1 shared publication- Joel M. Palefsky
University of California, San Francisco
1 shared publication Leolin Katsidzira
Faculty of Medicine and Health Sciences, Department of Medicine, University of Zimbabwe, Harare, Zimbabwe
1 shared publication
Latest Publications
- Open Access
- 5 October 2026
- Published by Springer Nature in BMC Cancer
Barriers and facilitators to colorectal cancer diagnosis in Zimbabwe: a qualitative study
- 5 October 2026
- Published by Springer Nature in BMC Cancer
Open AccessBarriers and facilitators to colorectal cancer diagnosis in Zimbabwe: a qualitative study
- Open Access
Emergency presentation of colorectal cancer in Africa: a scoping review
Objectives: This review identified and mapped the current evidence on emergency presentation of colorectal cancer in Africa. Design: Scoping review based on methodology by Arksey and O’Malley. Data sources: Medline (via PubMed), Embase and African Journals Online were searched between 29 January 2025 and 6 March 2025. Eligibility criteria: Studies published in English and describing the burden, risk factors and management options for emergency presentation of colorectal cancer in Africa were included. Full-text articles of all epidemiological study designs were considered with no publication date limit. Grey literature such as conference abstracts and letters to the editor were considered if sufficient study detail was provided to map data to the research questions. Data extraction and synthesis: Two independent reviewers extracted data from the included studies onto a standardised electronic form. Data were narratively synthesised using predefined themes. Results: Twenty-seven studies are included in this review. There was wide variability in reported emergency presentation colorectal cancer rates (8.3% to 64.9%). There were few data on early mortality, and none on long-term outcomes following surgery for colorectal cancer. Emergency presentation of colorectal cancer was characterised clinically by bowel obstruction, bowel perforation and peritonitis. Only one study reported on risk factors for emergency presentation of colorectal cancer. Use of diagnostic modalities was variable and depended on resource availability. Surgery was the mainstay of treatment. Endoscopic stenting was only available as a treatment option in South Africa. Conclusions: Emergency presentation of colorectal cancer is a significant clinical, oncological and health system metric, yet there is a dearth of evidence on the subject in the African context. Available evidence demonstrates the need for more studies on emergency presentation of colorectal cancer, focused on risk factors, prevalence, treatment options and short-term and long-term outcomes.
Open AccessEmergency presentation of colorectal cancer in Africa: a scoping review
Objectives: This review identified and mapped the current evidence on emergency presentation of colorectal cancer in Africa. Design: Scoping review based on methodology by Arksey and O’Malley. Data sources: Medline (via PubMed), Embase and African Journals Online were searched between 29 January 2025 and 6 March 2025. Eligibility criteria: Studies published in English and describing the burden, risk factors and management options for emergency presentation of colorectal cancer in Africa were included. Full-text articles of all epidemiological study designs were considered with no publication date limit. Grey literature such as conference abstracts and letters to the editor were considered if sufficient study detail was provided to map data to the research questions. Data extraction and synthesis: Two independent reviewers extracted data from the included studies onto a standardised electronic form. Data were narratively synthesised using predefined themes. Results: Twenty-seven studies are included in this review. There was wide variability in reported emergency presentation colorectal cancer rates (8.3% to 64.9%). There were few data on early mortality, and none on long-term outcomes following surgery for colorectal cancer. Emergency presentation of colorectal cancer was characterised clinically by bowel obstruction, bowel perforation and peritonitis. Only one study reported on risk factors for emergency presentation of colorectal cancer. Use of diagnostic modalities was variable and depended on resource availability. Surgery was the mainstay of treatment. Endoscopic stenting was only available as a treatment option in South Africa. Conclusions: Emergency presentation of colorectal cancer is a significant clinical, oncological and health system metric, yet there is a dearth of evidence on the subject in the African context. Available evidence demonstrates the need for more studies on emergency presentation of colorectal cancer, focused on risk factors, prevalence, treatment options and short-term and long-term outcomes.
- Open Access
- 14 November 2018
- Published by Springer Nature in BMC Public Health
- Vol. 18 (1) , 1260
Anal human papillomavirus infection in HIV-positive men and women at two opportunistic infections clinics in Harare, Zimbabwe
HIV-infected individuals are at increased risk of anal cancer; in the majority of cases this is linked to human papillomavirus (HPV) infection. Anal cancer screening is not routinely offered in Zimbabwe. A cross-sectional study was performed on 152 patients (88 females; 64 males) attending Opportunistic Infection Clinics at 2 tertiary hospitals between November 2014 and June 2015. Demographic data, immunological parameters and behavioural characteristics were collected. An anal swab was collected from each patient for HPV genotype testing. HPV testing was performed using MY09/MY11 PCR, followed by typing using the dot blot method. The mean age was 39.6 years (range, 18–69 years). Median CD4 count was 375 cells/μL. 96% were on antiretroviral therapy. Only one patient identified as a man who has sex with men. Of 122 samples tested for HPV, 54 were positive (44%). HPV was three times more common in females (60%) than males (20%). Being HPV-positive was associated with history of perianal warts, history of cervical intraepithelial neoplasia and having more than ten lifetime sexual partners. The most commonly detected high-risk HPV genotypes were HPV-58 (13%), HPV-31 (11%) and HPV-16 (9%). Nine patients harboured multiple high-risk HPV types. The two most commonly detected low-risk genotypes were HPV-11 (17%) and HPV-53 (11%). Overall anal HPV prevalence was 44% in this mostly heterosexual HIV-positive population. Oncogenic HPV types accounted for almost half of infections, supporting the need for surveillance of anal cancer in this population.
- 14 November 2018
- Published by Springer Nature in BMC Public Health
- Vol. 18 (1) , 1260
Open AccessAnal human papillomavirus infection in HIV-positive men and women at two opportunistic infections clinics in Harare, Zimbabwe
HIV-infected individuals are at increased risk of anal cancer; in the majority of cases this is linked to human papillomavirus (HPV) infection. Anal cancer screening is not routinely offered in Zimbabwe. A cross-sectional study was performed on 152 patients (88 females; 64 males) attending Opportunistic Infection Clinics at 2 tertiary hospitals between November 2014 and June 2015. Demographic data, immunological parameters and behavioural characteristics were collected. An anal swab was collected from each patient for HPV genotype testing. HPV testing was performed using MY09/MY11 PCR, followed by typing using the dot blot method. The mean age was 39.6 years (range, 18–69 years). Median CD4 count was 375 cells/μL. 96% were on antiretroviral therapy. Only one patient identified as a man who has sex with men. Of 122 samples tested for HPV, 54 were positive (44%). HPV was three times more common in females (60%) than males (20%). Being HPV-positive was associated with history of perianal warts, history of cervical intraepithelial neoplasia and having more than ten lifetime sexual partners. The most commonly detected high-risk HPV genotypes were HPV-58 (13%), HPV-31 (11%) and HPV-16 (9%). Nine patients harboured multiple high-risk HPV types. The two most commonly detected low-risk genotypes were HPV-11 (17%) and HPV-53 (11%). Overall anal HPV prevalence was 44% in this mostly heterosexual HIV-positive population. Oncogenic HPV types accounted for almost half of infections, supporting the need for surveillance of anal cancer in this population.